Physician profile
Jillian Roberson
NPI 1710548490
$1,465.06
in general payments reported to CMS, 2019-2025
17 companies · $216 in 2025
The $216 reported for 2025 was more than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $107 · 2023: $595 · 2024: $547 · 2025: $216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,109 · Education: $249.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,109.45 |
| Education | $248.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $585.47 | 2022-2025 | Opsumit, Uptravi |
| Glaxosmithkline, LLC. | $224.26 | 2023-2024 | Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $71.11 | 2023-2024 | Dupixent |
| United Therapeutics Corporation | $70.60 | 2023-2024 | Tyvaso |
| Axsome Therapeutics, INC. | $67.82 | 2023-2024 | Sunosi |
| Gilead Sciences, INC. | $66.03 | 2023-2024 | Veklury |
| Baxter Healthcare | $64.03 | 2023 | Hillrom - Life 2000 Ventilation System |
| Insmed, INC. | $43.40 | 2022-2025 | Arikayce |
| Jazz Pharmaceuticals INC. | $42.70 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.53 | 2023 | Ofev |
| Takeda Pharmaceuticals U.S.A., INC. | $36.05 | 2024 | Glassia |
| Amgen INC. | $33.66 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $29.39 | 2022-2024 | Fasenra |
| Merck Sharp & Dohme LLC | $26.35 | 2024 | Keytruda |
| Pulmonx Corporation | $25.03 | 2023 | Chartis Catheter, Zephyr Endobronchial Valve, Zephyr Delivery Catheter |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avadel Cns Pharmaceuticals, LLC | $21.88 | 2023 | Lumryz |
| Genzyme Corporation | $16.75 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jillian Roberson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.